Handelsavisen
prelaunch
Companies Healthcare PDEX.O
PD
PDEX.O NASDAQ Diversified Medical Equipment & Supplies

Pro-Dex Inc

$63,61
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
16,1 %
ROE
24,5 %
Net margin
13,5 %
Debt / equity
0,42
Beta
52w range
Volume
482
Day range
$64,75–$68,26
Prev close
$64,58
Open
$64,25
Next earnings
2026-08-09
Ex-dividend
TR 1Y
About

Pro-Dex Inc provides medical equipment, supplies, and distribution services within the healthcare sector, primarily generating revenue through the sale and distribution of medical products and services.

Business. Pro-Dex Inc (PDEX.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, focusing on capital equipment and consumables for medical procedures. Pro-Dex is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target70,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
70,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
Dimensional Fund Advisors, L.P.
largest disclosed fund holder
Profitability
24,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning PDEX.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to PDEX.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsFY 2026 earnings (expected)2026-08-09 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Pro-Dex Inc (PDEX.O) has recorded a series of notable new institutional holdings, marking the first analysis for this ticker with no prior basis for delta computation. The most significant addition involves an investor (ID 465) acquiring 144,571 shares valued at approximately $5.56 million as of December 31, 2025. This position represents a weight of roughly 0.008% in the investor's portfolio, signaling a substantial entry into the company's equity structure. Additional notable additions were detected across multiple reporting periods, further broadening the shareholder base. As of March 31, 2026, several investors initiated positions, including one (ID 487) holding 56,941 shares valued at $2.80 million, and another (ID 467) holding 33,114 shares valued at $1.63 million. Smaller but notable entries were also recorded for investors with IDs 499, 486, and 481 during the same quarter, with share counts ranging from 6,493 to 14,213. An earlier addition was noted for an investor (ID 466) who held 38,484 shares valued at $0.76 million as of June 30, 2024. These cumulative additions contribute to a total of 16 top holders currently identified for Pro-Dex Inc. The consistent pattern of "add" changes across different investors and timeframes suggests growing institutional interest in the company's stock. This expansion in the holder base is particularly relevant given the company's current analyst coverage, which stands at just one analyst. With no index membership and zero reported officers in the current dataset, the influx of new institutional capital may serve as a key indicator of market sentiment for Pro-Dex Inc. The accumulation of shares by multiple distinct entities highlights a shift in ownership composition that warrants monitoring for future liquidity and price stability implications.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Pro-Dex Inc (PDEX.O) is a healthcare services and equipment company that operates within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, focusing on capital equipment and consumables for medical procedures. Pro-Dex is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed in the available data.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Pro-Dex Inc maintains a relatively strong liquidity position, with a current ratio of 3.23, indicating the company can cover its short-term liabilities more than three times over with its current assets. However, the company's cash and equivalents amount to only $419,000, which is significantly lower than its long-term debt of $15,394,000, resulting in a negative net cash position. This suggests potential liquidity risk if short-term obligations exceed available cash.

    The company's profitability metrics are robust, with a return on equity (ROE) of 24.51% and a return on assets (ROA) of 14.67%. These figures exceed the typical thresholds for strong performance in the medical equipment and supplies industry, indicating efficient use of equity and assets to generate profit. The operating margin, calculated as operating income of $10,689,000 on revenue of $66,593,000, is approximately 16.05%, which is in line with industry expectations for firms of similar scale.

    Geographically and segment-wise, Pro-Dex Inc's revenue is not disclosed by region or business segment in the available data. However, the company's primary business activity is centered on medical equipment and supplies, which are typically less sensitive to geographic concentration risks compared to other healthcare subsectors. The absence of segment-specific data limits the ability to assess potential overreliance on a single product line or geographic market.

    Looking ahead, the company's growth trajectory appears stable, with no specific revenue growth rates provided in the input data. Analysts have assigned a mean price target of $70.00, with a median and high target also at $70.00, suggesting a consensus on the stock's fair value. The mean recommendation of 2.00 (on a scale from 1 to 5) indicates a "buy" rating, with one analyst recommending a "buy" and none recommending a "strong buy" or "strong sell".

    Risk factors for Pro-Dex Inc include its negative net cash position, which could limit flexibility in responding to market changes or capital needs. The company's liquidity risk is rated as medium, and while dilution risk is currently low, the absence of a significant equity cushion could expose the company to dilution pressure in the event of a capital raise. No specific dilution sources are disclosed in the input data, but the company's low dilution risk suggests that such events are not imminent.

    Recent events and disclosures for Pro-Dex Inc are not detailed in the input data. However, the company's financial performance and analyst ratings suggest a stable outlook, with no immediate signs of distress or volatility. The absence of recent filings or transcripts does not necessarily indicate a lack of activity, but it does limit the ability to assess the company's strategic direction or operational changes in the near term.

    Pro-Dex Inc (PDEX.O) has recorded a series of notable new institutional holdings, marking the first analysis for this ticker with no prior basis for delta computation. The most significant addition involves an investor (ID 465) acquiring 144,571 shares valued at approximately $5.56 million as of December 31, 2025. This position represents a weight of roughly 0.008% in the investor's portfolio, signaling a substantial entry into the company's equity structure. Additional notable additions were detected across multiple reporting periods, further broadening the shareholder base. As of March 31, 2026, several investors initiated positions, including one (ID 487) holding 56,941 shares valued at $2.80 million, and another (ID 467) holding 33,114 shares valued at $1.63 million. Smaller but notable entries were also recorded for investors with IDs 499, 486, and 481 during the same quarter, with share counts ranging from 6,493 to 14,213. An earlier addition was noted for an investor (ID 466) who held 38,484 shares valued at $0.76 million as of June 30, 2024. These cumulative additions contribute to a total of 16 top holders currently identified for Pro-Dex Inc. The consistent pattern of "add" changes across different investors and timeframes suggests growing institutional interest in the company's stock. This expansion in the holder base is particularly relevant given the company's current analyst coverage, which stands at just one analyst. With no index membership and zero reported officers in the current dataset, the influx of new institutional capital may serve as a key indicator of market sentiment for Pro-Dex Inc. The accumulation of shares by multiple distinct entities highlights a shift in ownership composition that warrants monitoring for future liquidity and price stability implications.

    Key takeaways
    • Pro-Dex Inc has a strong ROE of 24.51% and ROA of 14.67%, indicating efficient use of equity and assets to generate profit.
    • The company's liquidity position is strong with a current ratio of 3.23, but its negative net cash position raises concerns about short-term flexibility.
    • Analysts have assigned a mean price target of $70.00, with a "buy" recommendation, suggesting a positive outlook for the stock.
    • The company's risk profile is moderate, with medium liquidity risk and low dilution risk.
    • No segment or geographic revenue breakdown is available, limiting the ability to assess concentration risks.
    • The company's capital structure is relatively balanced, with a debt-to-equity ratio of 0.42.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $63,61
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $36.6M
    Net cash
    -$15.0M
    Current ratio
    3.2
    Debt / equity
    0.4
    ROA
    14.7%
    ROE
    24.5%
    Cash conversion
    -19.0%
    CapEx / revenue
    -1.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setPDEX 0,0% · rank #52 of 84

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs PDEX · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    -12,0 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    -14,8 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    -11,0 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    -17,6 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    -21,6 vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    -39,9 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    +6,3 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimateno estimate
    Revenueno estimateno estimate76,4M USD
    Operating incomeno estimateno estimateno estimate
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-07-20

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$70,00 · Median $70,00
    Low $70,00High $70,00
    Revenue surprise
    −12,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$70,00
    Mean$70,00
    Median$70,00
    High$70,00
    Spot$63,61
    +10.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin16,1 %Above P75
    Net Margin13,5 %Above P75
    ROE24,5 %Above P75
    Capex / Rev-1,9 %Above median
    D/E0,42Below median
    Cash Conv-0,19Bottom quartile

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Pro-Dex Inc Market data — financials · 2026-05-28
    • Pro-Dex Inc Market data — analyst estimates · 2026-05-28
    • Pro-Dex Inc Market data — ESG · 2026-05-28

    Ownership & reference

    Top holders

    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$3M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$2M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$6M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$2M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$1M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling0 buys · 7 sellsnet -$673K8 insiders · last 365d
    • Domingo Angelita RebamontanDirector · Common StockOther 19 @ $33,25$632 · 2026-07-23
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockOther 5 279 @ $62,74$331K · 2026-07-01
    • Charlton AlishaChief Financial Officer · Common StockOther 10 800 · 2026-07-01
    • Domingo Angelita RebamontanDirector · Common StockOther 2 488 @ $62,74$156K · 2026-07-01
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockOther 14 800 · 2026-07-01
    • Domingo Angelita RebamontanDirector · Common StockOther 6 800 · 2026-07-01
    • Charlton AlishaChief Financial Officer · Common StockOther 3 897 @ $62,74$244K · 2026-07-01
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockSold 50 @ $63,63$3K · 2026-05-22
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockSold 1 254 @ $62,93$79K · 2026-05-22
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockSold 2 824 @ $62,09$175K · 2026-05-22
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockSold 550 @ $63,92$35K · 2026-05-21
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockSold 1 918 @ $62,22$119K · 2026-05-21
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockSold 3 404 @ $62,96$214K · 2026-05-21
    • Domingo Angelita RebamontanDirector · Common StockSold 998 @ $47,24$47K · 2026-03-16
    • Domingo Angelita RebamontanDirector · Common StockOther 18 @ $34,36$618 · 2026-01-22
    • Philp Katrina Marie KramerDirector · Common StockOther 900 @ $32,73$29K · 2025-11-21
    • Philp Katrina Marie KramerDirector · Common StockOther 2 200 @ $32,70$72K · 2025-11-21
    • Charlton AlishaChief Financial Officer · Common StockOther 72 @ $30,83$2K · 2025-11-20
    • Van Kirk Richard Lee JrDirector, Chief Executive Officer · Common StockOther 72 @ $30,83$2K · 2025-11-20
    • Swenson Nicholas JohnDirector, 10% owner · Common StockOther 1 000 · 2025-11-20
    • Philp Katrina Marie KramerDirector · Common StockOther 1 000 · 2025-11-20
    • HOVDA DAVIDDirector · Common StockOther 1 000 · 2025-11-20
    • Farrell William James IIIDirector · Common StockOther 1 000 · 2025-11-20
    • Domingo Angelita RebamontanDirector · Common StockOther 72 @ $30,83$2K · 2025-11-20
    • Domingo Angelita RebamontanDirector · Common StockOther 1 000 · 2025-11-20

    Short positioning

    157.1Kshares short+5.7% vs prior
    1.62days to cover
    56.3%short of daily vol
    1fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    PDEX.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorM&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -27.8%Derived (calculated)
    • Current ratio (FY 2025-12-31): 4.03xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.50xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 7,889.4%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 30.8%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 3.1%Derived (calculated)
    • Total assets (annual): USD 62.26MSEC XBRL filing
    • Current liabilities (annual): USD 12.2MSEC XBRL filing
    • Total liabilities (annual): USD 20.62MSEC XBRL filing
    • Current assets (annual): USD 49.19MSEC XBRL filing
    • Cash & equivalents (annual): USD 5.27MSEC XBRL filing
    • Shareholders' equity (annual): USD 41.61MSEC XBRL filing
    • Shares outstanding (annual): 3.21MSEC XBRL filing
    • Net margin (FY 2025-06-30): 13.5%Derived (calculated)
    • Revenue (YoY) (2025-06-30 vs 2024-06-30): 23.7%Derived (calculated)
    • EPS (basic) (YoY) (2025-06-30 vs 2024-06-30): 347.5%Derived (calculated)
    • Cost of revenue (YoY) (2025-06-30 vs 2024-06-30): 19.8%Derived (calculated)
    • Gross margin (FY 2025-06-30): 29.3%Derived (calculated)
    • R&D expense (YoY) (2025-06-30 vs 2024-06-30): 14.0%Derived (calculated)
    • Operating cash flow (YoY) (2025-06-30 vs 2024-06-30): -127.0%Derived (calculated)
    • Net income (YoY) (2025-06-30 vs 2024-06-30): 322.1%Derived (calculated)
    • Operating income (YoY) (2025-06-30 vs 2024-06-30): 49.0%Derived (calculated)
    • Gross profit (YoY) (2025-06-30 vs 2024-06-30): 34.1%Derived (calculated)
    • EPS (diluted) (YoY) (2025-06-30 vs 2024-06-30): 345.0%Derived (calculated)
    Showing 24 of 57 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    2026-07-23INSIDERDomingo Angelita Rebamontan transacted 19 sh — Director ~$1k
    2026-07-01INSIDERVan Kirk Richard Lee Jr transacted 5.3k sh — Director, Chief Executive Officer ~$331k
    2026-07-01INSIDERCharlton Alisha transacted 10.8k sh — Chief Financial Officer
    2026-07-01INSIDERDomingo Angelita Rebamontan transacted 2.5k sh — Director ~$156k
    2026-07-01INSIDERVan Kirk Richard Lee Jr transacted 14.8k sh — Director, Chief Executive Officer
    2026-07-01INSIDERDomingo Angelita Rebamontan transacted 6.8k sh — Director
    2026-07-01INSIDERCharlton Alisha transacted 3.9k sh — Chief Financial Officer ~$244k
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER14 institutional position changes flagged
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-17FILINGFORM 8-K →
    2026-05-22 00:00 UTCINSIDER6 insider transactions — 2026-05 · net sell $626k
    2026-05-22 00:00 UTCINSIDER6 insider transactions — 2026-05 · net sell $626k
    2026-05-22INSIDERVan Kirk Richard Lee Jr sold 50 sh — Director, Chief Executive Officer ~$3k
    2026-05-22INSIDERVan Kirk Richard Lee Jr sold 1.3k sh — Director, Chief Executive Officer ~$79k
    2026-05-22INSIDERVan Kirk Richard Lee Jr sold 2.8k sh — Director, Chief Executive Officer ~$175k
    2026-05-21INSIDERVan Kirk Richard Lee Jr sold 550 sh — Director, Chief Executive Officer ~$35k
    2026-05-21INSIDERVan Kirk Richard Lee Jr sold 1.9k sh — Director, Chief Executive Officer ~$119k
    2026-05-21INSIDERVan Kirk Richard Lee Jr sold 3.4k sh — Director, Chief Executive Officer ~$214k
    2026-04-30FILINGFORM 8-K →
    2026-04-30FILINGQUARTERLY REPORT →
    2026-03-27FILINGFORM 8-K →
    2026-03-16INSIDERDomingo Angelita Rebamontan sold 998 sh — Director ~$47k
    2026-02-12FILINGFORM 8-K →
    2026-01-29FILINGFORM 8-K →
    2026-01-29FILINGFORM 10-Q →
    2026-01-22 00:00 UTCINSIDER1 insider transaction — 2026-01
    2026-01-22 00:00 UTCINSIDER1 insider transaction — 2026-01
    2026-01-22INSIDERDomingo Angelita Rebamontan transacted 18 sh — Director ~$1k
    2025-12-19FILINGFORM 8-K →
    2025-11-21 00:00 UTCINSIDER12 insider transactions — 2025-11 · $108k gross
    Showing the 40 most recent of 57 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage